Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma

Table 3

Response to second-line chemotherapy according to pathology and regime.

Histology	Chemo	CR	PR	SD	PD	NA
Synovial	Dox		1 (0.3%)		3 (0.8%)	1 (0.3%)
	Ifos	1 (0.3%)	4 (1.1%)	2 (0.5%)	15 (4.0%)	1 (0.3%)
	Dox/Ifos	1 (0.3%)	2 (0.5%)	1 (0.3%)	2 (0.5%)
	Other	2 (0.5%)		4 (1.1%)	13 (3.4%)
Liposarcoma	Dox	1 (0.3%)	1 (0.3%)	3 (0.8%)	2 (0.5%)
	Ifos		2 (0.5%)	3 (0.8%)	14 (3.7%)
	Dox/Ifos			5 (1.3%)	1 (0.3%)
	Other		1 (0.3%)	5 (1.3%)	6 (1.6%)
Leiomyosarcoma	Dox		1 (0.3%)	7 (1.8%)	12 (3.2%)	1 (0.3%)
	Ifos		1 (0.3%)	4 (1.1%)	27 (7.1%)	2 (0.5%)
	Dox/Ifos		1 (0.3%)		2 (0.5%)
	Other		2 (0.5%)	14 (3.7%)	59 (15.6%)
Other:	Dox			6 (1.6%)	23 (6.1%)
	Ifos	1 (0.3%)	2 (0.5%)	11 (2.9%)	31 (8.2%)	2 (0.5%)
	Dox/Ifos				6 (1.6%)
	Other	2 (0.5%)	2 (0.5%)	11 (2.9%)	50 (13.2%)	2 (0.5%)

Dox: doxorubicin, Ifos: Ifosfamide, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, NA: not assessable.